文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

脑寡转移瘤调强放疗同步推量:ISIDE-BM-1 I期研究

Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost in Patients With Brain Oligometastases: A Phase 1 Study (ISIDE-BM-1).
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2016-09-23

这项I期研究评估标准直线加速器调强放疗同步推量全脑放疗治疗<5个脑转移瘤的最大耐受剂量。全脑PTV统一30 Gy/10次,转移灶PTV逐步升至35、40、45、50 Gy。30例入组,3例出现剂量限制性毒性,50 Gy/10次组可耐受。

要点

  • 全脑PTV统一30 Gy/10次,转移灶PTV同步推量35–50 Gy。
  • 剂量限制性毒性3例:35 Gy组无,40 Gy组G3皮肤,50 Gy组G3神经毒性和脑出血。
  • 50 Gy/10次同步推量方案可耐受,中位生存12个月,1年OS 53%。

核心结论

  • 标准直线加速器调强放疗同步推量全脑放疗中,转移灶推量至50 Gy/10次可耐受。

研究设计与样本

  • 前瞻性I期剂量递增研究,纳入<5个脑转移瘤患者,共30例,按转移灶PTV剂量35、40、45、50 Gy分4个剂量组。

主要发现

  • 30例中3例出现剂量限制性毒性:40 Gy组1例G3皮肤毒性,50 Gy组1例G3神经毒性、1例脑出血。
  • 急性毒性多为G1–2,皮肤19例、神经10例;未观察到晚期毒性。
  • 中位生存12个月,1年总生存率53%。

关键数值与推荐

  • 全脑PTV为全脑加3 mm边距,处方30 Gy/10次(3 Gy/次)。
  • 转移灶PTV为MRI T1增强肿瘤加3 mm各向同性边距,剂量递增至35、40、45、50 Gy/10次。
  • 剂量限制性毒性在6例队列治疗后的3个月随访时评估。

临床怎么用

  • 对<5个脑转移瘤的姑息治疗,可考虑全脑30 Gy/10次同步转移灶推量至50 Gy/10次。
  • 治疗中需关注皮肤和神经系统急性毒性,50 Gy组注意脑出血风险。

局限性

  • I期剂量递增研究,样本量30例,主要目的是确定最大耐受剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the maximum tolerated dose of intensity modulated radiation therapy simultaneous integrated boost whole-brain radiation therapy for palliative treatment of patients with <5 brain metastases using a standard linear accelerator. MATERIALS AND METHODS: The whole brain plus 3-mm margin was defined as the planning target volume (PTVwb), whereas each brain metastasis, defined as the contrast-enhancing tumor on MRI T1 scans, plus a 3-mm isotropic margin, was defined as metastases PTV (PTVm). Radiation therapy was delivered in 10 daily fractions (2 weeks). Only the dose to PTVm was progressively increased in the patient cohorts (35 Gy, 40 Gy, 45 Gy, 50 Gy), whereas the PTVwb was always treated with 30 Gy (3 Gy per fraction) in all patients. The dose-limiting toxicity was evaluated providing that 3 months of follow-up had occurred after the treatment of a 6-patient cohort. RESULTS: Thirty patients were enrolled in the study (dose PTVm: 35 Gy, 8 patients; 40 Gy, 6 patients; 45 Gy, 6 patients; 50 Gy, 10 patients). The number of treated brain metastases was 1 in 18 patients, 2 in 5 patients, 3 in 6 patients, and 4 in 1 patient. Three patients experienced dose-limiting toxicity: 1 patient at dose level 2 presented grade 3 (G3) skin toxicity; 1 patient at dose level 4 presented G3 neurologic toxicity; and 1 patient at the same level showed brain hemorrhage. Most patients showed G1 to 2 acute toxicity, in most cases skin (n=19) or neurologic (n=10). Twenty-seven were evaluable for response: 6 (22%) stable disease, 18 (67%) partial response, and 3 (11%) complete response. Median survival and 1-year overall survival were 12 months and 53%, respectively. No patient showed late toxicity. CONCLUSIONS: In this first prospective trial on the use of intensity modulated radiation therapy simultaneous integrated boost delivered with a standard linear accelerator in patients with brain oligometastases, a boost dose up to 50 Gy in 10 fractions was tolerable according to the study design.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Ferro M, Chiesa S, Macchia G, et al. Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost in Patients With Brain Oligometastases: A Phase 1 Study (ISIDE-BM-1). Int J Radiat Oncol Biol Phys. 2016. PMID: 27843034. doi:10.1016/j.ijrobp.2016.09.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。